Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Weibel, Stephanie ^a   Hofmann, Elisabeth ^a   Basse Luesebrink, Thomas Christian ^a,b   Donat, Ulrike ^a   Seubert, Carolin ^a   Adelfinger, Marion ^a   Gnamlin, Prisca ^a   Kober, Christina ^a   Frentzen, Alexa ^e   Gentschev, Ivaylo ^a,e   Jakob, Peter Michael ^a,b   Szalay, Aladar A ^a,c,d,e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Research Center Magnetic Resonance Bavaria   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^e GENELUX CORPORATION   (United States)

Author keywords

Lung cancer; Malignant effusion; Oncolytic virotherapy; VEGF

Indexed keywords

ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SPECIFICITY; FEMALE; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PLEURA EFFUSION; POXVIRUS INFECTION; SINGLE DRUG DOSE; TISSUE LEVEL; TREATMENT RESPONSE; TUMOR INVASION; TUMOR XENOGRAFT; VACCINIA VIRUS;

ANIMALS; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; INJECTIONS, SUBCUTANEOUS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PLEURAL EFFUSION, MALIGNANT; SINGLE-CHAIN ANTIBODIES; TREATMENT OUTCOME; VACCINIA VIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876801085     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-106     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Canc J Clin 2012, 62:10-29.
2. Uzbeck MH, Almeida FA, Sarkiss MG, Morice RC, Jimenez CA, Eapen GA, Kennedy MP. Management of malignant pleural effusions. Adv Ther 2010, 27:334-347. 10.1007/S12325-010-0031-8, 20544327.
3. Bennett R, Maskell N. Management of malignant pleural effusions. Curr Opin Pulm Med 2005, 11:296-300.
4. Lombardi G, Zustovich F, Nicoletto MO, Donach M, Artioli G, Pastorelli D. Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches. Am J Clin Oncol 2010, 33:420-423. 10.1097/COC.0b013e3181aacbbf, 19858695.
5. Grove CS, Lee YCG. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 2002, 8:294-301. 10.1097/00063198-200207000-00009, 12055392.
6. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Fidler IJ. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000, 157:1893-1903. 10.1016/S0002-9440(10)64828-6, 1885766, 11106562.
7. Yano S, Nokihara H, Hanibuchi M, Parajuli P, Shinohara T, Kawano T, Sone S. Model of malignant pleural effusion of human lung adenocarcinoma in SCID mice. Oncol Res 1997, 9:573-579.
8. Hamed EA, El-Noweihi AM, Mohamed AZ, Mahmoud A. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. Respirology 2004, 9:81-86. 10.1111/j.1440-1843.2003.00529.x, 14982607.
9. Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Canc Res 2000, 6:957-965.
10. Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 2000, 5(Suppl 1):45-50.
11. Matsumori Y, Yano S, Goto H, Nakataki E, Wedge SR, Ryan AJ, Sone S. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res 2006, 16:15-26.
12. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?. Oncologist 2009, 14:1242-1251. 10.1634/theoncologist.2009-0109, 20008305.
13. Van TT, Hanibuchi M, Goto H, Kuramoto T, Yukishige S, Kakiuchi S, Sato S, Sakaguchi S, Dat LT, Nishioka Y. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model. Respirology 2012, 17(6):984-990. Aug, 10.1111/j.1440-1843.2012.02193.x, 22574723.
14. Bourke MG, Salwa S, Harrington KJ, Kucharczyk MJ, Forde PF, de Kruijf M, Soden D, Tangney M, Collins JK, O'Sullivan GC. The emerging role of viruses in the treatment of solid tumours. Canc Treat Rev 2011, 37:618-632.
15. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Des 2010, 16:3-10. 10.2174/138161210789941847, 20214614.
16. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Canc Lett 2007, 254:178-216.
17. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Canc 2005, 5:965-976.
18. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007, 4:101-117. 10.1038/ncponc0736, 17259931.
19. Rowan K. Oncolytic viruses move forward in clinical trials. J Natl Canc Inst 2010, 102:590-595.
20. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012, 30:658-670. 10.1038/nbt.2287, 22781695.
21. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM, Szalay AA. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Canc Res 2007, 67:10038-10046.
22. Zhang Q, Liang C, Yu YA, Chen N, Dandekar T, Szalay AA. The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genomics 2009, 282:417-435. 10.1007/s00438-009-0475-1, 2746888, 19701652.
23. Yu Z, Li S, Brader P, Chen N, Yu YA, Zhang Q, Szalay AA, Fong Y, Wong RJ. Oncolytic vaccinia therapy of squamous cell carcinoma. Mol Canc 2009, 8:45.
24. Gentschev I, Muller M, Adelfinger M, Weibel S, Grummt F, Zimmermann M, Bitzer M, Heisig M, Zhang Q, Yu YA. Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68. PLoS One 2011, 6:e22069. 10.1371/journal.pone.0022069, 3133637, 21779374.
25. Gentschev I, Donat U, Hofmann E, Weibel S, Adelfinger M, Raab V, Heisig M, Chen N, Yu YA, Stritzker J, Szalay AA. Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. J Biomed Biotechnol 2010, 2010:489759. 2850154, 20379368.
26. Advani SJ, Buckel L, Chen NG, Scanderbeg DJ, Geissinger U, Zhang Q, Yu YA, Aguilar RJ, Mundt AJ, Szalay AA. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts. Clin Canc Res 2012, 18:2579-2590.
27. Weibel S, Raab V, Yu YA, Worschech A, Wang E, Marincola FM, Szalay AA. Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Canc 2011, 11:68.
28. Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, Szalay AA. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci USA 2009, 106:12915-12920. 10.1073/pnas.0900660106, 2722284, 19617539.
29. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, Winkler F. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010, 16:116-122. 10.1038/nm.2072, 20023634.
30. Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, Donat U, Weibel S, Chen NG, Yu YA, Zhang Q. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One 2012, 7:e37239. 10.1371/journal.pone.0037239, 3352892, 22615950.
31. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Canc Res 2000, 60:4959-4967.
32. Iankov ID, Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB, Gastineau D, Ikeda Y, Ingle JN, Russell SJ, Galanis E. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Canc Res Treat 2010, 122:745-754.
33. Iankov ID, Allen C, Federspiel MJ, Myers RM, Peng KW, Ingle JN, Russell SJ, Galanis E. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus. Mol Ther 2012, 20:1139-1147. 10.1038/mt.2012.4, 22334023.
34. Cheng D, Rodriguez RM, Perkett EA, Rogers J, Bienvenu G, Lappalainen U, Light RW. Vascular endothelial growth factor in pleural fluid. Chest 1999, 116:760-765. 10.1378/chest.116.3.760, 10492284.
35. Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Canc Immunol Immunother 1999, 48:396-400.
36. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, Mutti L, Procopio A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001, 193:468-475. 10.1002/path.824, 11276005.
37. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Canc Res 2005, 65:671-680.
38. Pichelmayer O, Gruenberger B, Zielinski C, Raderer M. Bevacizumab is active in malignant effusion. Ann Oncol 1853, 2006:17.
39. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know?. Br J Canc 2009, 100:865-869.
40. Risau W. Mechanisms of angiogenesis. Nature 1997, 386:671-674.
41. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, Senger DR. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991, 174:1275-1278. 10.1084/jem.174.5.1275, 2118980, 1940805.
42. Prager GW, Lackner EM, Krauth MT, Unseld M, Poettler M, Laffer S, Cerny-Reiterer S, Lamm W, Kornek GV, Binder BR. Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. Mol Oncol 2010, 4:150-160. 10.1016/j.molonc.2010.01.002, 20106729.
43. Lee TH, Avraham HK, Jiang S, Avraham S. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J Biol Chem 2003, 278:5277-5284. 10.1074/jbc.M210063200, 12446667.
44. Hayashi Y, Torisu M. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils. Surgery 1990, 107:74-84.
45. Katano M, Torisu M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction. Surgery 1983, 93:365-373.
46. Torisu M, Katano M, Kimura Y, Itoh H, Takesue M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 1983, 93:357-364.